These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30038571)

  • 1. Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR
    Wang Y; Lai H; Fan X; Luo L; Duan F; Jiang Z; Wang Q; Leung ELH; Liu L; Yao X
    Front Pharmacol; 2018; 9():728. PubMed ID: 30038571
    [No Abstract]   [Full Text] [Related]  

  • 2. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR
    Xu J; Zhu GY; Cao D; Pan H; Li YW
    Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
    Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
    World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
    Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
    Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.
    Sun P; Qu Y; Wang Y; Wang J; Wang X; Sheng J
    J Cancer; 2021; 12(13):3900-3908. PubMed ID: 34093797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compound 15c, a Novel Dual Inhibitor of EGFR
    Chen G; Bao Y; Weng Q; Zhao Y; Lu X; Fu L; Chen L; Liu Z; Zhang X; Liang G
    Front Pharmacol; 2019; 10():1533. PubMed ID: 31998131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor.
    Pratama MRF; Poerwono H; Siswodihardjo S
    J Basic Clin Physiol Pharmacol; 2019 Dec; 30(6):. PubMed ID: 31855568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer.
    Mao J; Ma L; Shen Y; Zhu K; Zhang R; Xi W; Ruan Z; Luo C; Chen Z; Xi X; Chen S
    Cell Death Dis; 2018 Sep; 9(10):963. PubMed ID: 30237564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines.
    Shao H; Wells A
    Front Oncol; 2023; 13():1163504. PubMed ID: 37333807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma.
    Fawwaz M; Mishiro K; Nishii R; Makino A; Kiyono Y; Shiba K; Kinuya S; Ogawa K
    Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33809064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFR
    Tian L; Li X; Lv Z; Yang Y; Wang L; Xu D; Ma X; Xu Y
    Bioorg Med Chem; 2022 Nov; 74():117052. PubMed ID: 36288657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.
    Chen LY; Molina-Vila MA; Ruan SY; Su KY; Liao WY; Yu KL; Ho CC; Shih JY; Yu CJ; Yang JC; Rosell R; Yang PC
    Lung Cancer; 2016 Apr; 94():46-53. PubMed ID: 26973206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
    Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
    Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.